Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ixekizumab versus adalimumab in children with juvenile idiopathic arthritis (ERA and juvenile psoriatic arthritis)
2023-507184-19-00Phase 3Authorised
- Sponsor
- Eli Lilly and Company
- Start
- Oct 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 11
01
Overview
Phase 3, open-label trial of ixekizumab in juvenile idiopathic arthritis, enthesitis-related (JIA-ERA), juvenile ankylosing spondylitis (JAS) and juvenile psoriatic arthritis (JPsA) (2 arms), sponsored by Eli Lilly and Company. Primary endpoint: JIA ACR30 response rate. Planned start Oct 2023; status: authorised.
02
Drugs
ixekizumab
03
Conditions
juvenile idiopathic arthritis, enthesitis-related (JIA-ERA)juvenile ankylosing spondylitis (JAS)juvenile psoriatic arthritis (JPsA)
Beyond the preview
Go deeper on 2023-507184-19-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507184-19-00.